Articles by Dr. Natalie Hughes
Clene Receives FDA Green Light for CNM-Au8 Accelerated Approval Pathway in ALS Treatment
Clene advances CNM-Au8 for ALS treatment after FDA confirms accelerated approval pathway eligibility based on neurofilament light biomarker data.
InspireMD Receives FDA Approval for SwitchGuard Neuro Protection System CGUARDIANS III Pivotal Trial
InspireMD secures FDA IDE approval for CGUARDIANS III pivotal study of SwitchGuard Neuro Protection System, advancing stroke prevention technology development.
Akebia Therapeutics Vadadustat Shows Significant Mortality Reduction in New Kidney Disease Analysis
Akebia Therapeutics announces Vadadustat post-hoc analysis published in JASN shows statistically significant reduction in mortality and hospitalization for kidney disease patients.
FDA Approves Palazestrant for Breast Cancer Amidst Data Concerns
The U.S. Food and Drug Administration (FDA) has granted approval for palazestrant, a novel breast cancer treatment developed by Pfizer and Arvinas. This decision comes despite some concerns raised about the drug's clinical trial data, marking a significant development in breast cancer therapy.
Spinogenix Tazbentetol Shows Neuroprotective Effects in Glaucoma and Diabetic Retinopathy Preclinical Studies at ARVO 2026
Spinogenix presents preclinical data showing Tazbentetol (SPG302) reduces retinal cell loss and preserves visual function in eye disease models at ARVO 2026.
Harmonization of Clinical Trial Regulations: PMDA, TGA & CDSCO Compared
This article compares the clinical trial regulations of PMDA, TGA, and CDSCO, focusing on their impact on drug development and patient safety.
ANVISA Regulatory Changes: Impact on Fast-Track Approvals for Oncology Drugs
This article examines how recent ANVISA regulatory changes affect the fast-track approval process for oncology drugs, enhancing patient access to treatments.
Mounjaro FDA Approval: Eli Lilly's Tirzepatide Milestone
Eli Lilly's tirzepatide, marketed as Mounjaro, has achieved FDA approval, marking a significant regulatory milestone. This dual GIP and GLP-1 receptor agonist is now more accessible for type 2 diabetes treatment in the US.
Phathom Pharmaceuticals VOQUEZNA Sales Surge 104% in Q1 2026, Company Maintains Profitability Guidance
Phathom Pharmaceuticals reports $58.3M Q1 revenue from VOQUEZNA, up 104% year-over-year, with 1.35M prescriptions filled and profitability expected Q3 2026.
Aquestive Therapeutics Faces Securities Fraud Lawsuit Despite Anaphylm FDA Review Progress
Aquestive Therapeutics hit with class action lawsuit alleging misleading investor communications about Anaphylm sublingual film FDA approval timeline.
Antibody-Drug Conjugates in Breast Cancer: Enhertu vs. Trodelvy in EU Market
This article compares Enhertu and Trodelvy, two leading antibody-drug conjugates, in their effectiveness for breast cancer treatment in the EU market.
IgA Nephropathy Market to Reach New Heights by 2036 as Novartis Zigakibart and Novel Immunotherapies Drive Growth
IgA nephropathy market expansion driven by Novartis Zigakibart, Roche Sefaxersen, and emerging immunotherapies through 2036 with improved patient outcomes.
Regeneron Q1 2026 Earnings: Dupixent Sales Surge 33% to $4.9B, EYLEA HD Shows Strong Growth
Regeneron reports 19% revenue growth to $3.6B in Q1 2026, driven by Dupixent's 33% sales increase to $4.9B and EYLEA HD's 52% growth to $468M.
Sprout Pharmaceuticals Addyi (Flibanserin) Maker Named Top 10 Most Influential Health Company by TIME 2026
Sprout Pharmaceuticals, maker of Addyi (flibanserin), joins TIME's 10 most influential health companies of 2026 following FDA approval expansion and growth.
PMDA SAKIGAKE Designation: Accelerating Innovation in Japan's Pharma Sector
The PMDA SAKIGAKE Designation is transforming Japan's pharmaceutical landscape, expediting the development of innovative drugs like XYZ for cancer treatment.
CAR-T Therapy Clinical Trials: Insights from ASCO 2026 and FDA Approval Implications
Discover the latest insights on CAR-T therapy from ASCO 2026 and understand the potential implications of FDA approval for innovative cancer treatments.
Bayer Presents 13 Stroke Research Abstracts at ESOC 2026, Including Asundexian Phase III Trial Data
Bayer showcases 13 stroke research abstracts at ESOC 2026, featuring late-breaking Phase III OCEANIC-STROKE trial analyses of Asundexian for stroke prevention.
Pfizer's ELREXFIO Shows Significant Progression-Free Survival Improvement in Multiple Myeloma Phase 3 Trial
Pfizer's ELREXFIO meets primary endpoint in MagnetisMM-5 Phase 3 trial, showing statistically significant progression-free survival improvement for relapsed multiple myeloma patients.
EMA Conditional Marketing Authorizations: What You Need to Know
Explore the essentials of EMA Conditional Marketing Authorizations, focusing on drug XYZ for rare diseases and the implications for pharmaceutical companies.
FDA's New AI Validation Framework in Oncology Drug Development
The FDA's new AI validation framework aims to streamline oncology drug development, ensuring more effective cancer therapies through advanced technology.